Financial Times Global Pharma and Biotech Summit

9 – 11 November 2020, virtual event

Transforming the pharma business for growth

As they move past the immediate challenge of contributing solutions to deal with the Covid-19 pandemic, pharmaceutical and biotech companies will face a changed world. Despite the many devastating impacts, the crisis represents an opportunity to innovate at a quicker pace, refine growth strategies and build new partnerships. The Financial Times Global Pharma and Biotech Summit brings together industry leaders and experts to share insights and perspectives on the critical issues set to re-shape the sector in the wake of the COVID-19 pandemic.

Complimentary registration for ICON clients

As a lead sponsor, ICON is pleased to offer senior executives at clients and other third parties, a complimentary pass for this premier digital event supported by the world's best journalism (a saving of GBP 699). Passes / tickets are limited to maximum two per client - to be registered simply complete the short form and we will contact you.

Featured speakers include:

Paul Hudson, CEO, Sanofi

David Loew, CEO, Ipsen

Anthony Fauci, Director of National Institute of Allergy and Infectious Diseases (NIAID)

Roger Connor, President of Global Vaccines, GSK

Richard Hatchett, CEO, Coalition for Epidemic Preparedness and Innovation (CEPI)

Teresa Graham, Head of Product Strategy, Roche

Bertrand Dobson, Chief Digital Officer, Novartis

Marianne De Backer, Head of Pharmaceuticals Business Development and Licensing

Bayer

Steven Pearson, Founder and President, Institute for Clinical and Economic Review (ICER)

Jose Baselga, Executive Vice President, Research & Development, Oncology

AstraZeneca

Susanne Schaffert, President, Oncology, Novartis

Libby Driscoll, Vice President of US Neurosciences, Eli Lilly & Company

ICON speakers:

Dr. Nuala Murphy

Dr. Nuala Murphy

President, Clinical Research Services

Monday, November, 09, 4:20 PM - 4:45 PM GMT (25 Min)

Presentation and fireside chat with Clive Cookson, Science Editor, Financial Times, on "Decentralised & hybrid trials - models for increased resilience and better outcomes".

Thomas O'Leary

Thomas O'Leary

Chief Information Officer

Tueday, November 10, 11:15 AM - 12:05 PM GMT (50 Min)

Panel: How Technology is Transforming R&D

Pharma companies are using technologies to include advances in AI, functional genomics and other innovations to take a patient focused approach, to accelerate the pace of medicines discovery, to reduce the costs of clinical trials and deliver drugs to patients faster. And advances in the use of technology in R&D is receiving a boost with regulators including the FDA releasing guidelines on the use of RWE/RWD, and with their growing acceptance of novel patient-centred and digital endpoints in the approval of new drugs. What are the ways in which AI and big data are making/will make a meaningful impact in R&D, and where is pharma on its AI /data journey? How successful will pharma companies ultimately be in finding new ways to apply AI to big data sets to discover new drugs, given the complexity of the underlying biology?

Tarek Sherif, Co-CEO and Co-Founder, Medidata

Andrew Hopkins, CEO, ExscIentia

Moderator: Sarah Neville, Global Pharmaceuticals Editor, Financial Times

Deirdre Albertson

VP, Women's Health

Tuesday, November 10, 5:20 PM - 6:00 PM GMT (40 Min)

Panel: Women's Health

Women’s healthcare has been largely underserved and underfunded, yet there is significant scope for innovation. Issues to include stigma and the challenge of attracting scientists to this specialisation have impeded market growth, yet the market opportunity is significant. Women account for half the global population and they are the leading decision makers in term of family health and healthcare spend. The health and pharma industry are rallying to the cause, and the field of femtech, for instance, has expanded significantly in recent years. As the issue of under representation of women in drug trials hits the headlines, meanwhile, the business of women’s health is gradually moving to the spotlight. What are the emerging opportunities, and how are early pioneers in this market addressing the market?

 

Bob Swann

Senior Principal, Global Pricing and Market Access

Roundtable: Advanced therapy medicinal products: HTA evaluation and implications for pricing and reimbursement

Moderator: Bob Swann

Are current Health Technology Assessment (HTA) processes fit for purpose for advanced therapy medicinal products (ATMPs)?

An invite-only discussion on:

  • Payer and industry perspectives on ATMPs
  • Implications of HTA evaluation of short term evidence for products providing long term benefit
  • Learnings from Europe and the US
  • What industry can do to optimize ATMP price and reimbursement in a HTA world